| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |